Facial Aging Improvement Case Study Using a Novel Combination of Retinol, Niacinamide, and Terminalia Chebula

July 2022 | Volume 21 | Issue 7 | 784 | Copyright © July 2022


Published online June 30, 2022

doi:10.36849/JDD.6621

Marc Z. Handler MDa,b,c, Alison Adams-Woodford BA LEd, Patty Ayres LE CMLTe, Giorgiana Giancola PhDf, Isabel Diaz BAg

aDepartment of Dermatology, Metropolitan Hospital, New York, NY
bDepartment of Dermatology, Rutgers New Jersey Medical School, Newark, NJ
cDermatology, Hackensack Meridian School of Medicine, Nutley, NJ
dR&D and Communications, Physicians Care Alliance (PCA) Skin, Scottsdale, AZ
ePhysicians Care Alliance (PCA) Skin, Scottsdale, AZ
fScientific Affairs, Colgate-Palmolive Company, Piscataway, NJ
gDermal Clinical Research, Colgate-Palmolive Company, Piscataway, NJ

Abstract
For decades, retinoids have been considered the gold standard of treatment for a variety of skin conditions.1,2 As the bioavailable form of vitamin A, retinoic acid has demonstrated the ability to reduce skin discoloration, stimulate collagen production, reduce rhytids, improve acne, and uneven skin texture.3,4 Retinoic acid is a potent drug with high bioavailability. Challenges with such a product include skin sensitivity and retinoid dermatitis.1,5 This potential irritation and discomfort may hinder patient compliance reducing visible results. The non-prescription vitamin A ingredient retinol is an effective and less irritating alternative, as it is converted into retinoic acid within the skin, causing little to no irritation when used topically. Intensive Age Refining Treatment: 0.5% pure retinol night by PCA SKIN® contains 0.5% retinol, protected and delivered into the skin with a multi-layered liposomal delivery technology. This development addresses the inherent instability of retinol,1,2,3 as well as the mitigation of irritation with the goal of enhancing patient compliance and visible results. This formulation also features niacinamide and terminalia chebula to further support the anti-aging benefits of retinol. The 12-week in vivo use of this potent, yet non-irritating retinol topical demonstrates improved patient compliance and satisfaction due to tolerability and enhanced efficacy in the improvement in overall signs of healthy skin.

J Drugs Dermatol. 2022;21(7):784-788. doi:10.36849/JDD.6621

INTRODUCTION

Many patients avoid retinoic acid due to skin irritation after application, thus reducing perceived efficacy. Retinol is a less irritating topical that carries many of the same benefits as retinoic acid with less irritation and is available without a prescription. Additional ingredients, such as niacinamide and terminalia chebula have demonstrated antiaging benefits as well.7,8 Using a liposomal delivery system, a novel formulation was produced to provide an effective and tolerable facial treatment of rhytids, redness, discoloration, and texture. A 12-week facial study was conducted to evaluate the efficacy of a novel topical on the reduction of fine lines, erythema, dyspigmentation, as well as the improvement in skin texture. A self-perception questionnaire was also completed by all participants at the endpoint of the study.

CASE

In order to evaluate the efficacy of the PCA SKIN® Intensive Age Refining Treatment: 0.5% pure retinol night, a group of Fitzpatrick Type II women between the ages of 36 and 61 were recruited with an N=16 (subjects enrolled) and N= 13 (subjects completed and analyzed) for the study. Three withdrew due to issues unrelated to the study.

Following completion of an IRB approved informed consent (US Investigational Review Board, Miami, FL) and meeting all inclusion criteria and none of the exclusion criteria, baseline images were captured before the start of the study at week 0 as well as every two weeks until the study endpoint at week 12. For all participants, images and filter data were captured of the left, right, and front of the face using the Canfield Visia® imaging technology (model Generation 7, software version 7). Filter images specifically analyzed were those tracking changes in brown spots, red areas, wrinkles, and skin texture. Visia® images of all participants were evaluated by the dermatologist investigator.
Close Menu